SHILPAMED Stock Overview
Engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Shilpa Medicare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹485.60 |
| 52 Week High | ₹561.60 |
| 52 Week Low | ₹228.50 |
| Beta | 0.78 |
| 1 Month Change | -11.77% |
| 3 Month Change | 14.76% |
| 1 Year Change | 105.15% |
| 3 Year Change | -13.65% |
| 5 Year Change | 41.97% |
| Change since IPO | 659.15% |
Recent News & Updates
Recent updates
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jan 26
Here's Why I Think Shilpa Medicare (NSE:SHILPAMED) Is An Interesting Stock
Jan 14Shilpa Medicare (NSE:SHILPAMED) Shareholders Have Enjoyed A 54% Share Price Gain
Jan 03Could The Shilpa Medicare Limited (NSE:SHILPAMED) Ownership Structure Tell Us Something Useful?
Dec 22Is There More To The Story Than Shilpa Medicare's (NSE:SHILPAMED) Earnings Growth?
Dec 11How Much Are Shilpa Medicare Limited (NSE:SHILPAMED) Insiders Taking Off The Table?
Nov 30How Is Shilpa Medicare's (NSE:SHILPAMED) CEO Compensated?
Nov 16Earnings Release: Here's Why Analysts Cut Their Shilpa Medicare Limited (NSE:SHILPAMED) Price Target To ₹611
Nov 04Shareholder Returns
| SHILPAMED | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.0% | -1.8% | -1.9% |
| 1Y | 105.2% | 51.6% | 41.0% |
Return vs Industry: SHILPAMED exceeded the Indian Pharmaceuticals industry which returned 54.1% over the past year.
Return vs Market: SHILPAMED exceeded the Indian Market which returned 41% over the past year.
Price Volatility
| SHILPAMED volatility | |
|---|---|
| SHILPAMED Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SHILPAMED has not had significant price volatility in the past 3 months.
Volatility Over Time: SHILPAMED's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,179 | Vishnukanth Bhutada | www.vbshilpa.com |
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the United States, Europe, and internationally. It’s primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables.
Shilpa Medicare Limited Fundamentals Summary
| SHILPAMED fundamental statistics | |
|---|---|
| Market cap | ₹42.09b |
| Earnings (TTM) | ₹318.74m |
| Revenue (TTM) | ₹11.52b |
132.0x
P/E Ratio3.7x
P/S RatioIs SHILPAMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHILPAMED income statement (TTM) | |
|---|---|
| Revenue | ₹11.52b |
| Cost of Revenue | ₹4.08b |
| Gross Profit | ₹7.44b |
| Other Expenses | ₹7.12b |
| Earnings | ₹318.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.67 |
| Gross Margin | 64.61% |
| Net Profit Margin | 2.77% |
| Debt/Equity Ratio | 52.0% |
How did SHILPAMED perform over the long term?
See historical performance and comparison